43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement38th Annual Miami Breast Cancer Conference® - Abstracts
Volume 35
Issue suppl 1
Pages: 23

1University of Texas Medical Branch, Galveston, TX (roweiser@utmb.edu).

2University of Texas Medical Branch, Galveston, TX.

3The University of Texas MD Anderson Cancer Center, Houston, TX.

Background

Invasive lobular carcinoma (ILC) is traditionally considered less responsive to chemotherapy. While Oncotype recurrence score (RS) has been validated to identify high-risk patients who benefit from chemotherapy, some studies have questioned its relevance in patients with ILC. We sought to better characterize the potential use of RS in patients with ILC.

Materials and Methods:

The National Cancer Database (NCDB) was used to identify 3505 women with stage I to III, T1-T3, N1, hormone receptor–positive, HER2-negative ILC between 2010 and 2016, with an available RS. A similar cohort of 20,928 patients with invasive ductal carcinoma (IDC) was identified for comparison. Univariate analyses were used to identify variables correlating with chemotherapy use and 5-year survival. The Kaplan-Meier method was used to calculate 5-year survival. Subgroup analysis according to RS was performed.

Results

The mean age of ILC and IDC patients was 60.9 (±10.4) and 59.5 (±11.0) years, respectively. Patients with ILC had larger tumors, lower-grade disease, and a greater quantity of involved lymph nodes, and they received more mastectomies compared with patients with IDC. Fewer patients with ILC received chemotherapy compared with those with IDC (28.5% vs 34.9%; P <.0001). Patients with ILC had a lower mean (SD) RS (15.3 [±6.7] vs 17.1 [±10.1]; P <.0001), as well as a lower percentage of patients with high RS, defined as >25 (5.9% vs 14.7%; P <.0001). Among patients with high RS with ILC, 66.7% received chemotherapy compared with 79.4% of similar patients with IDC. A statistically significant absolute 5-year survival advantage was found in association with chemotherapy use in high-RS patients with ILC (11.8%), comparable with that in similar patients with IDC (16.2%). Intermediate-RS patients (RS, 12-25) with ILC and IDC demonstrated a more modest, but still statistically significant, survival advantage with chemotherapy: 4.9% and 3.0%, respectively (Table).

TABLE. Five-Year Survival (%) by Chemotherapy Use, Histology, and RS

TABLE. Five-Year Survival (%) by Chemotherapy Use, Histology, and RS

Conclusions

Patients with high-RS ILC are treated less often with chemotherapy compared with similar patients with IDC. Nevertheless, our data show an association between survival benefit and chemotherapy use in patients with high-RS ILC, and even intermediate-RS ILC. Such benefit should be taken into account when considering adjuvant chemotherapy in these patients.

Expert Commentary

Expert Commentary

Articles in this issue

1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
45 Neoadjuvant Chemotherapy Use in Elderly Patients
45 Neoadjuvant Chemotherapy Use in Elderly Patients